Brainstorm Cell Therapeutics Inc. (BCLI) vs CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN)

Brainstorm Cell Therapeutics Inc. and CollPlant Biotechnologies Ltd. Sponsored ADR are both Biotechnology companies. Brainstorm Cell Therapeutics Inc. and CollPlant Biotechnologies Ltd. Sponsored ADR are of similar size ($7.0M and $7.0M). Brainstorm Cell Therapeutics Inc. has the higher net margin (0.00% vs −3,934.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Brainstorm Cell Therapeutics Inc. leads on 10 and CollPlant Biotechnologies Ltd. Sponsored ADR on 2.

Valuation

Metric BCLI CLGN Biotechnology median
P/E n/m n/m 8.50
P/S n/m 16.34 9.71
P/B n/m 1.76 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 24.21 9.21
Earnings yield (119.40%) (263.11%) (33.15%)
Free cash flow yield (47.20%) (216.45%) (25.50%)

Profitability

Metric BCLI CLGN Biotechnology median
Gross margin 0.00% (321.70%) 65.16%
Operating margin 0.00% (3,900.94%) 0.00%
Net margin 0.00% (3,934.91%) 0.00%
Free cash flow margin 0.00% (3,522.64%) 0.00%
Return on equity 119.20% (161.98%) (56.36%)
Return on assets (627.43%) (101.59%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BCLI CLGN Biotechnology median
Revenue growth (TTM) — (86.76%) 6.02%
EPS growth (last fiscal year) 51.95% 35.17% 30.26%
Revenue growth, 5-year CAGR — (17.32%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BCLI CLGN Biotechnology median
Debt to equity (0.11) 0.00 0.00
Current ratio 0.03 1.57 4.72
Net debt to EBITDA (0.10) 0.56 0.96

Dividend

Metric BCLI CLGN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BCLI CLGN Biotechnology median
Market cap 6.99m 6.96m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack